ArticleFrontiers in aging neuroscience2026
The changing epidemiology of infection-associated mortality in Alzheimer's disease in the United States, 1999-2024.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infections are major immediate causes of death in patients with Alzheimer's disease, trends across infection subtypes remain poorly characterized. We examined temporal trends, demographic geographic disparities, COVID-19-era patterns, projected infection-associated mortality in United States, 1999-2024. Methods: Using CDC Multiple Cause of Death database, infection-associated AD deaths were classified into six subtypes. AAMRs and temporal trends were estimated using joinpoint regression. Kitagawa decomposition assessed demographic age-specific contributions to sex disparities, Bayesian Structural Time Series models projected burden through 2034. Results: Among 2,342,153 AD-related deaths, 308,045 (13.2%) were infection-associated. Overall infection-associated AAMR declined by 57.6% (AAPC -3.72% per year), diverging from rising AD mortality. Respiratory infections showed the steepest decline (AAMR -68.3%) with improvements across all regions and urbanization strata. By contrast, genitourinary infections were the only subtype with rising burden-absolute deaths increased 75.1%, rural AAMR rose 73.1% over 1999-2020, and central trend-continuation projections suggest a possible further increase, particularly over the near-term horizon, although uncertainty becomes substantial in the longer term. Kitagawa decomposition showed that the female excess in genitourinary mortality was attributable to higher age-specific female rates rather than to population age structure-uniquely among the subtypes examined (cumulative risk effect +11,337; 47.4% of the female excess; cumulative female deaths exceeding male by 170%); the increase in this risk component over time was directionally consistent but of model-dependent statistical significance. Mortality was overwhelmingly concentrated in the oldest age stratum ( ≥ 85-year rate 2,516-fold that of < 65 years). During the COVID-19 era, overall infection-associated AD mortality fell below pre-pandemic projections, with genitourinary infections showing the smallest cumulative deficit of any subtype. Hispanic individuals had the highest AAMR by 2024, while Non-Hispanic Black individuals maintained elevated septicemia mortality throughout. Conclusion: Although infection-associated AD mortality declined substantially, a growing genitourinary infection burden widened across sex, rural, and racial strata, with trend-continuation projections suggesting a possible further increase, particularly over the near-term horizon. These findings, combined with external clinical evidence on infection prevention, suggest that targeted measures-including CAUTI prevention, sex-specific bladder health programs, and rural infection prevention investment-merit priority attention as baby boomers enter peak AD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.